- Home
- BCTX vs HBIO Comparison
BCTX vs HBIO Comparison
Compare BCTX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- HBIO
- Stock Information
- Founded
- BCTX 2014
- HBIO 1901
- Country
- BCTX Canada
- HBIO United States
- Employees
- BCTX N/A
- HBIO N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- BCTX Health Care
- HBIO Industrials
- Exchange
- BCTX Nasdaq
- HBIO Nasdaq
- Market Cap
- BCTX 23.5M
- HBIO 22.5M
- IPO Year
- BCTX N/A
- HBIO 2000
- Fundamental
- Price
- BCTX $3.11
- HBIO $0.51
- Analyst Decision
- BCTX Strong Buy
- HBIO Buy
- Analyst Count
- BCTX 1
- HBIO 2
- Target Price
- BCTX $32.00
- HBIO $3.00
- AVG Volume (30 Days)
- BCTX 359.2K
- HBIO 35.3M
- Earning Date
- BCTX 06-16-2025
- HBIO 08-07-2025
- Dividend Yield
- BCTX N/A
- HBIO N/A
- EPS Growth
- BCTX N/A
- HBIO N/A
- EPS
- BCTX N/A
- HBIO N/A
- Revenue
- BCTX N/A
- HBIO $91,397,000.00
- Revenue This Year
- BCTX N/A
- HBIO N/A
- Revenue Next Year
- BCTX N/A
- HBIO $9.75
- P/E Ratio
- BCTX N/A
- HBIO N/A
- Revenue Growth
- BCTX N/A
- HBIO N/A
- 52 Week Low
- BCTX $2.78
- HBIO $0.28
- 52 Week High
- BCTX $29.40
- HBIO $3.60
- Technical
- Relative Strength Index (RSI)
- BCTX 44.63
- HBIO 54.14
- Support Level
- BCTX $2.78
- HBIO $0.47
- Resistance Level
- BCTX $3.16
- HBIO $0.55
- Average True Range (ATR)
- BCTX 0.19
- HBIO 0.07
- MACD
- BCTX -0.01
- HBIO -0.00
- Stochastic Oscillator
- BCTX 40.24
- HBIO 50.68
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.